<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625035</url>
  </required_header>
  <id_info>
    <org_study_id>Lianhua Qingwen 2022</org_study_id>
    <nct_id>NCT05625035</nct_id>
  </id_info>
  <brief_title>Lianhua Qingwen for the Rehabilitation of Patient With Coronavirus Infection</brief_title>
  <official_title>Efficacy and Safety of Lianhua Qingwen in the Long-Term Rehabilitation of Patients With Coronavirus Infection: a Randomized, Open-Label, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients with coronavirus infection usually have fever, respiratory symptoms, headache,&#xD;
      toothache, muscle soreness, physical decline, and so on, while others are asymptomatic&#xD;
      patients. It is urgent to find drugs to improve the long-term rehabilitation of symptomatic&#xD;
      patients with coronavirus infection and decrease the duration of viral shedding in both&#xD;
      symptomatic and asymptomatic patients. This study aims to investigate the efficacy and safety&#xD;
      of Lianhua Qingwen capsules in patients with coronavirus infection. The duration of viral&#xD;
      shedding and symptoms before discharge, as well as the negative conversion ratio and&#xD;
      disappearance ratio of main symptoms after 7-day treatment, will be evaluated. 6-month&#xD;
      follow-up will be performed to evaluate the effect of Lianhua Qingwen on all infection events&#xD;
      and the long-term rehabilitation of the symptoms induced by coronavirus infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all Infection events</measure>
    <time_frame>From discharge to 6 months</time_frame>
    <description>Recurrence coronavirus infection or any new infection events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of viral shedding</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative conversion ratio</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive conversion ratio</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of main symptoms before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of main symptoms</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence frequency of main clinical symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of main clinical symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>both systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>7 days</time_frame>
    <description>both systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>both systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection events except SARS-CoV-2</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of fever</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of fever</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of fever</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of respiratory symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of respiratory symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of respiratory symptoms before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of respiratory symptoms</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of nasal congestion or runny nose</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of nasal congestion or runny nose</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of nasal congestion or runny nose before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of nasal congestion or runny nose</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of chest distress</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of chest distress</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of chest distress before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of chest distress</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of palpitations</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of palpitations</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of palpitations before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of palpitations</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of pharyngeal discomfort</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of pharyngeal discomfort</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of pharyngeal discomfort before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of pharyngeal discomfort</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of headache</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of headache</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of headache before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of headache</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of dizziness</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of dizziness</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of dizziness before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of dizziness</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toothache</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of toothache</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of toothache before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of toothache</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of muscle soreness</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of muscle soreness</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of muscle soreness before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of muscle soreness</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of physical decline</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of physical decline</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of physical decline before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of physical decline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of gastrointestinal symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of gastrointestinal symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of gastrointestinal symptoms before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of gastrointestinal symptoms</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of urinary symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of urinary symptoms</measure>
    <time_frame>From discharge to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of urinary symptoms before discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance ratio of urinary symptoms</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Coronavirus</condition>
  <condition>Traditional Chinese Medicine</condition>
  <arm_group>
    <arm_group_label>Lianhua Qingwen plus conventional therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lianhua Qingwen capsules</intervention_name>
    <description>Lianhua Qingwen capsules: 4 capsules once, three times daily</description>
    <arm_group_label>Lianhua Qingwen plus conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed SARS-CoV-2 Infection by virus testing;&#xD;
&#xD;
          -  ≥18 years of age;&#xD;
&#xD;
          -  informed consent provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  overt bacterial infection in the respiratory tract resulting from common pathologies,&#xD;
             including primary immunodeficiency disease, acquired immunodeficiency syndrome,&#xD;
             congenital respiratory malformation, congenital heart disease, gastroesophageal reflux&#xD;
             disease, and abnormal lung development;&#xD;
&#xD;
          -  asthma treated daily, chronic airway disease, respiratory bacterial infections (e.g.,&#xD;
             purulent tonsillitis), acute tracheobronchitis, sinusitis, otitis media, and further&#xD;
             respiratory tract pathologies potentially affecting the trial's data analysis;&#xD;
&#xD;
          -  common pulmonary diseases (e.g., severe pulmonary interstitial lesions and&#xD;
             bronchiectasis) confirmed by chest CT;&#xD;
&#xD;
          -  severe pneumonia requiring ventilator use;&#xD;
&#xD;
          -  previous or present diseases potentially affecting trial participation or influencing&#xD;
             study outcome, based on the investigator's judgment;&#xD;
&#xD;
          -  pregnancy or lactation in women;&#xD;
&#xD;
          -  participation in a clinical study in the past 3 months;&#xD;
&#xD;
          -  history of allergy to ≥2 drugs or foods or known allergy to the drug's constituents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panpan Hao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panpan Hao, MD</last_name>
    <phone>86-18560086593</phone>
    <email>panda.how@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>International Convention and Exhibition Center Shelter Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>831400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panpan Hao, MD</last_name>
      <phone>86-18560086593</phone>
      <email>panda.how@sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Pan-Pan Hao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

